|  Help  |  About  |  Contact Us

Publication : Effect of growth differentiation factor-15 secreted by human umbilical cord blood-derived mesenchymal stem cells on amyloid beta levels in in vitro and in vivo models of Alzheimer's disease.

First Author  Kim DH Year  2018
Journal  Biochem Biophys Res Commun Volume  504
Issue  4 Pages  933-940
PubMed ID  30224067 Mgi Jnum  J:272467
Mgi Id  MGI:6280392 Doi  10.1016/j.bbrc.2018.09.012
Citation  Kim DH, et al. (2018) Effect of growth differentiation factor-15 secreted by human umbilical cord blood-derived mesenchymal stem cells on amyloid beta levels in in vitro and in vivo models of Alzheimer's disease. Biochem Biophys Res Commun 504(4):933-940
abstractText  Alzheimer's disease (AD), which is the most common progressive neurodegenerative disease, causes learning and memory impairment. The pathological progress of AD can derive from imbalanced homeostasis of amyloid beta (Abeta) in the brain. In such cases, microglia play important roles in regulating the brain Abeta levels. In the present study, we found that human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) can increase, through paracrine action, the ability of microglial cells to clear Abeta. In order to identify the associated paracrine factors, a secretome of hUCB-MSCs co-cultured with Abeta-treated BV2 microglial cells was analyzed using a human cytokine protein array. As a result, growth differentiation factor-15 (GDF-15) was identified as a predominant candidate, and its association with Abeta clearance by microglial cells was investigated in vitro and in a 5XFAD mouse model. When Abeta-treated BV2 cells were treated with exogenous recombinant GDF-15, the Abeta levels in the culture medium decreased. Moreover, GDF-15 injection in the brain parenchyma of 5XFAD mice also led to decrease in Abeta plaques. In contrast, co-culture of BV2 cells and hUCB-MSCs treated with GDF-15-specific siRNA did not influence the Abeta levels in the culture medium. To elucidate how these phenomena are related, we confirmed that GDF-15 specifically increases insulin-degrading enzyme (IDE) expression in microglial cells through TGFbeta receptor type II (TGFbetaRII), both in vitro and in vivo. These findings suggest that hUCB-MSCs promote the Abeta clearance ability of microglial cells through regulation of GDF-15 secretion, thus elucidating a therapeutic mechanism for AD.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

4 Bio Entities

0 Expression